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Summary The aim of our study was to evaluate the pharmacodynamic effects of 1-
day treatment with formoterol, tiotropium and their combination in patients with
acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Twenty-one
(19 males, mean age 7278 years, mean FEV1 38714% of predicted values) patients
with mild to moderate AECOPD were enrolled. Patients received formoterol (12 mg
deliver via Modulites b.i.d.), tiotropium (18mg dry powder capsules delivered via
HandiHalers once daily), and their combination, in randomized sequence. Serial
measurements of FEV1, FVC, IC, SpO2 and HR were performed over 24 h. Formoterol,
tiotropium, and their combination significantly improved the area under curves
(AUCs) for FEV1, FVC and IC over 12 and 24 h. The mean FEV1, FVC and IC AUC012 h
and AUC024 h after formoterol and tiotropium combination were significantly higher
than formoterol and tiotropium alone, whereas the differences between the two
single drugs were not statistically significant. Formoterol, either alone or in
combination with tiotropium, elicited a significantly faster onset of action, and
combination elicited a greater maximum bronchodilation than both single drugs in
terms of FEV1 and FVC. After 24 h the bronchodilating effect of the three treatments
disappeared, with the exception of the combination on FEV1. The results of this
study have documented that, although the time course of the effects of evaluated
drugs differs significantly from that in stable COPD, with a shorter bronchodilation
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both for tiotropium and formoterol, these two long-acting bronchodilators appear to
also be complementary in mild to moderate AECOPD.
& 2006 Elsevier Ltd. All rights reserved.
Introduction
Acute exacerbations of chronic obstructive pul-
monary disease (AECOPD) are associated with
symptoms that include increased dyspnea, cough,
and sputum volume, as well as changes in sputum
colour.1 Symptoms are of fundamental importance
and are the primary concern of the patient; it is
generally a change in symptoms that prompts
contact with healthcare professionals. Conse-
quently, one of the most important goal of
treatment of AECOPD is the fast resolution of
symptoms.2
COPD exacerbations have also been associated
with decrements in pulmonary function.1 Since in
most patients with AECOPD, there appears to be a
component of the worsened airflow obstruction
that is particularly responsive to bronchodilators,3
which can lead to a symptoms reduction by
affecting hyperinflation,4 bronchodilators are con-
sidered central in the symptomatic control of
AECOPD.2,3 In effect, patients presenting with
AECOPD should be given short-acting inhaled
bronchodilators at high doses.5
In the acute exacerbation, there is little evi-
dence conclusively establishing that any specific
agent has superior efficacy as compared to others.
However, there may be some advantages to the
longer-acting agents in that there will be prolonged
bronchodilation. In fact, the use of long-acting
b2-agonists has recently been suggested as a poten-
tial option in the therapy of AECOPD,6–9 although
these agents are currently not approved for use in
this pathologic condition. In particular, formoterol
has been proposed for the symptomatic treatment of
AECOPD.10–11 since its onset of action is similar to
that of salbutamol in patients with COPD.12,13.
There is enough evidence in the literature that
combination therapy with b2-adrenoceptor agonists
and anticholinergics is effective and has a good
safety profile.5 Unfortunately, to our best knowl-
edge, no study has still investigated the impact of a
combination therapy with formoterol and an antic-
holinergic agent in AECOPD, although there is
documentation that in patients with stable COPD,
treatment with a combination of formoterol and
ipratropium bromide is more effective than a
combination of salbutamol and ipratropium.14
The introduction into the market of tiotropium
bromide, a long-acting anticholinergic bronchodi-
lator that maintains bronchodilation for at least
24 h, allowing once-daily administration,15 and
induces greater bronchodilator effect than ipra-
tropium bromide,16 has offered a new drug able to
improve dynamic lung hyperinflation and exertional
dyspnea.17,18 The documentation that tiotropium
alone or in combination with once-daily formoterol
improved mean trough and average FEV1 and
trough FVC values from baseline,19 and this even
to a greater extent than twice-daily formoterol,20
suggests the need for also exploring the effect of a
combination of formoterol and tiotropium in the
therapy of AECOPD.
The aim of our study was, therefore, to evaluate
the pharmacodynamic effects of 1 day treatment of
formoterol, tiotropium and their combination in
patients with AECOPD. Considering that conven-
tional chlorofluorocarbon (CFC)-containing pressur-
ized metered-dose inhalers (pMDIs) generate
coarse, fast-moving clouds which can impede the
optimal deposition of drug in the lung, a further
problem in patients suffering from AECOPD, in this
study we used a formoterol Modulites solution
formulation. In fact, the Modulites inhaler, which
has been developed to provide stable and uniform
dose delivery using hydrofluoroalkane (HFA)—
instead of CFC-based formulations, has been
designed to improve the characteristics of the
cloud emitted from the device to make the
coordination of inspiration with drug delivery
easier for the patient,21 and this is extremely
convenient for patients with an AECOPD.
Material and methods
Subjects
Twenty-one (19 males, mean age 7278, range
58–86 years, mean smoke history 54726 pack-
years, mean body mass index 27.075.1 kg/m2)
patients with mild to moderate AECOPD22 were
enrolled (Table 1). Mean baseline FEV1 was 0.99 l
(95% CI: 0.77–1.21, 38714% of predicted values)
and mean forced vital capacity (FVC) was 1.83 l
(95% CI: 1.48–2.18, 56719% of predicted values).
All patients fulfilled the criteria proposed by GOLD
guidelines for COPD2; they had cough, sputum
production, or dyspnea, and/or a history of
exposure to risk factors for the disease. The
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diagnosis was confirmed by spirometry (post-
bronchodilator FEV1o80% of the predicted value,
and FEV1/FVCo70%). Patients with allergic rhinitis,
atopy, positive skin test, or with a total blood
eosinophil count over 400ml3 were excluded.
Patients’ domiciliary treatment consisted in long
acting b2-agonists (formoterol 12 mg b.i.d. and
salmeterol 50 mg b.i.d. in 12 and 9 patients,
respectively), anticholinergic (oxitropium bromide
200 mg b.i.d. in 18 patients) and inhalatory steroids
(budesonide 400 mg b.i.d. and fluticasone
250–500 mg b.i.d. in 12 and 9 patients, respec-
tively). No patient was in treatment with theophil-
line. Acute exacerbations of COPD, according to
Anthonisen et al.,1 were defined by the presence of
almost two of three of the following symptoms:
increase dyspnoea, increased volume of sputum
and purulence of sputum. The study was carried out
according to the rules of the declaration of
Helsinki. It was approved by the local ethical
committee. All patients provided written informed
consent to participate in the study.
Protocol
This was a double-blind, double-dummy, cross-over,
randomized study. Patients received formoterol
(12 mg deliver via Modulites b.i.d.), tiotropium
(18 mg dry powder capsules delivered via HandiHa-
lers once daily), and their combination, in rando-
mized sequence on days 1, 3 and 5. During days 2
and 4 patients were treated with salbutamol (last
assumption almost 8 h before the study drugs
inhalation). The washout period between the test
days was at least 48 h in order to reduce the carry-
over effect of tiotropium that has been described in
patients with stable COPD.23 No other oral bronch-
odilators were allowed during the study. All
patients were treated with systemic corticosteroids
(40mg of prednisolone or equivalent) and anti-
biotics (ciprofloxacin, levofloxacin, amoxicillin-
clavulanate7aminoglycosides) according to treat-
ing doctor. Consumption of cola drinks, coffee, tea,
and smoking prior and during the investigation were
avoided.
Physiological measurements
On test days, measurements of FEV1, FVC, inspira-
tory capacity (IC) (Elite DL, MedGraphicss, St Paul,
MN, USA), oxygen saturation (SpO2) (by pulse
oximetry Nonin Medical, Inc. Plymouth, MN, USA)
and heart rate (HR) were recorded just before
dosing and 30, 60, 120, 180, 240, 360, 480,
600, 720, and 1440min after the study drug
administration.
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Table 1 Anthropometric data, smoking habit and pulmonary function of patients.
Patient Sex Age (years) Smoking habit
(pack-years)
FEV1 (% predicted) FVC (% predicted)
1 M 71 50 32 46
2 M 75 50 36 55
3 M 86 50 25 33
4 M 63 90 49 59
5 M 72 60 25 36
6 F 61 21 39 62
7 M 60 100 17 23
8 M 64 30 25 34
9 F 80 21 36 51
10 M 75 40 66 73
11 M 64 20 62 80
12 M 68 50 27 48
13 M 84 80 59 92
14 M 74 80 21 47
15 M 80 22 45 53
16 M 83 20 34 44
17 M 77 80 31 53
18 M 75 40 57 93
19 M 58 80 43 76
20 M 73 60 35 57
21 M 76 80 27 52
Mean7SD 7278 54726 38714 56719
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Statistical analysis
This was a pilot study and the first known
comparison of formoterol, tiotropium, and their
combination in patients with AECOPD. In view of
the lack of previous experiences, no statistical
hypotheses were drawn and consequently no formal
sample size calculation was made. The use of pilot
study such as the current study in clinical research
is a well-established scientific procedure and only
through the use of a pilot study can statisticians
clarify data distributions and determine appropri-
ate sample sizes for full-scale clinical trials.
According to the number of enrolled patients, a
Kolmogorov–Smirnov test was performed before
the data analysis in order to examine the data
distribution. This test documented that the entire
evaluated variable were distributed in a normal
way, and then we used parametric tests for data
management.
Comparison of baseline characteristics among
the 3 days and the treatments were performed by
ANOVA analysis for repeated measurements, while
post-hoc analysis was performed by Bonferroni-
test. As an expression of the total effect of each
treatment, the areas under the FEV1, FVC and IC
time responses curves (AUCs) were calculated for
each patient by means of the trapezoidal rule.
Comparison of AUCs and maximum response values
among the three treatments were performed as
before described. In the time course of bronchodi-
lating effect, the comparisons vs. baseline values
were performed by paired t-test. Data are pre-
sented as mean7standard deviations (SD) in the
text with 95% confidence interval, while in figures
bars represent standard error (SE). A probability
level o0.05 (Po0:05) was considered significant
for all tests. Data were analysed by Statistical
Package for the Social Science (version 13.0, SPSS,
Chicago, USA).
Results
All the 21 patients completed the study. There
were no significant differences among the baseline
FEV1, FVC and IC values in the 3 days of treatment
(P ¼ 0:218, 0.325, and 0.570, respectively) and
between the three treatments (P ¼ 0:338, 0.265,
and 0.680, respectively).
FEV1, FVC and IC areas under the curves
Formoterol, tiotropium, and their combination
significantly (Po0:01) improved the AUCs for
FEV1, FVC and IC over 12 and 24 h (Fig. 1). The
mean FEV1, FVC and IC AUC012 h and AUC024 h
after formoterol and tiotropium combination were
significantly higher than formoterol and tiotropium
alone (all, Po0:01), whereas the differences
between the two single drugs were not statistically
significant.
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Figure 1 Mean changes (7SE) from pre-dosing value on
each of the treatment days in FEV1 (2a), FVC (2b) and IC
(2c) area under curve (AUC) during the first 12 h (AUC
0–12 h) and 24 h (AUC 0–24 h). Formoterol (12 mg deliver
via Modulites b.i.d.), tiotropium (18 mg dry powder
capsules delivered via HandiHalers once daily), and
combination (formoterol+tiotropium).
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Time course of bronchodilating effect
The actual data of FEV1, FVC and IC before and
after the three treatments are shown in Fig. 2. The
three therapies elicited a different bronchodilation
profile, with a faster onset of action for formoterol
alone or in combination with tiotropium. At 30min,
the combination of formoterol and tiotropium
induced a significant higher improvement in FEV1
and FVC than those obtained after single treatment
administration (Po0:01 for all comparisons). The
difference between formoterol and tiotropium
resulted statistically significant (Po0:01). At the
same time, the combination provided a higher IC
than tiotropium (Po0:05) but not than formoterol.
At 12 h, the mean increase in FEV1 form pre-dosing
value were 0.019 l (95% CI: 0.026–0.063; not
significant) for formoterol, 0.097 l (95% CI:
0.033–0.161; Po0:01) for tiotropium and 0.118 l
(95% CI: 0.055–0.182; Po0:01) for the combination.
According to IC and FVC values, at 12 h the
bronchodilation effect of the two single drugs
disappeared, whereas the combination elicited a
persistent bronchodilation (Po0:05). Twelve hours
after the inhalation of formoterol associated to
tiotropium the mean FVC increase was 0.150 l (95%
CI: 0.003–0.296; Po0:05) and in IC was 0.135 l (95%
IC: 0.009–0.261; Po0:05). At this time the differ-
ences among treatments were significant, with an
higher mean FEV1 for the tiotropium and the
combination vs. formoterol (Po0:01), a signifi-
cantly higher mean FVC for the combination vs. the
single drugs (Po0:01) and an higher mean IC for the
combination vs. formoterol (Po0:05) but not vs.
tiotropium. After 24 h the bronchodilating effect of
the three treatments disappeared (Fig. 2), with the
exception of the combination on FEV1 (increase of
0.039 l—95% CI 0.005–0.073: Po0:05). At this time,
post-hoc analysis found a significantly higher mean
FEV1 after the inhalation of formoterol and
tiotropium combination than after the two single
drugs (Po0:05) and a higher mean FVC after the
combination than after formoterol administration
(Po0:05).
Maximum response
The mean maximum increase in FEV1 from pre-
dosing value on each of the dosing days were 0.222 l
(95% CI: 0.139–0.305) for formoterol, 0.150 l (95%
CI: 0.089–0.210) for tiotropium and 0.327 l (95% CI:
0.236–0.418) for the combination and occurred 2 h
after formoterol and combination and 3 h after
tiotropium inhalation. All comparisons between
drugs resulted significant (combination vs. both
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Figure 2 Mean changes in FEV1 (1a), FVC (1b), IC (1c) and SpO2 (1d) from pre-dosing value on each of the treatment
days up to 24 h. Formoterol (12mg deliver via Modulites b.i.d.), tiotropium (18 mg dry powder capsules delivered via
HandiHalers once daily), and combination (formoterol+tiotropium). *Po0.01; yPo0.05.
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single drugs: post-hoc Po0:01; formoterol vs.
tiotropium: post-hoc Po0:05).
The mean maximum increase in FVC from pre-
dosing value on each dosing day were 0.272 l (95%
CI: 0.157–0.387) for formoterol, 0.218 l (95% CI:
0.132–0.303) for tiotropium and 0.428 l (95% CI:
0.270–0.586) for the combination and occurred 1 h
after formoterol and 2 h after inhalation of tiotro-
pium and the combination. The differences be-
tween combination and both the two single drugs
were significant (post-hoc Po0:05).
The mean maximum increase in IC from pre-
dosing value on each of the dosing days were 0.243 l
(95% CI: 0.103–0.384) for formoterol, 0.188 l (95%
CI: 0.058–0.317) for tiotropium and 0.366 l (95% CI:
0.214–0.518) for the combination and occurred 2 h
after formoterol and combination and 3 h after
inhalation of tiotropium. The difference between
treatments was border-line significant (ANOVA
P ¼ 0:053).
Pulse rate and oxygen saturation
The actual data of SpO2 before and after the three
treatments are shown in Fig. 2. There were no
significant differences between the baseline oxy-
gen saturation (SpO2) in the 3 days (P ¼ 0:128) and
in the three treatment groups (P ¼ 0:124). The
mean SpO2 AUC024 h was significantly higher after
the inhalation of the combination (2275 h l, CI 95%:
2251–2299) than after the inhalation of both
formoterol (mean 2271 h l, CI 95%: 2247–2296) and
tiotropium (mean 2270 h l, CI 95%: 2245–2295)
alone (Po0:05 for both the comparisons). No
statistically significant modifications from baseline
and between the three treatments in HR were
found.
Discussion
The aim of the present study was to investigate the
pharmacodynamic effects of 1 day treatments with
formoterol delivered by Modulites, tiotropium and
their combination in patients with AECOPD. The
results documented that the combination of for-
moterol and tiotropium induced a greater overall
bronchodilation, as expressed by AUC both after 12
than 24 h, than the single drugs. As expected,
formoterol elicited a fast onset of action that,
intriguingly, was enhanced by the concomitant
inhalation of tiotropium. In our opinion, this finding
is important because one of the goals of AECOPD
management is the prompt resolution of symptoms2
that can also be achieved by a rapid bronchodila-
tion. Interestingly, the maximum bronchodilation
obtained by the combination was higher than that
recorded after the administration of the single
drugs. On the other hand, the bronchodilator effect
of formoterol disappeared after 12 h and that of
tiotropium after 24 h. This trend was in accord with
the documentation that the duration of the
bronchodilator effect of short acting, inhaled ß2
agonists is decreased in COPD exacerbation.24 The
speculative explanation of the shorter bronchodila-
tion that we have found may be the increase of
bronchial inflammation, which is present during
exacerbation.25,26 It is a possibility that the
inflammation may modify the pharmacokinetic
and pharmacodynamic properties of inhalatory
drugs, although we must emphasize that the
amount of bronchodilation we observed, expressed
as maximum response, did not differ significantly
by that found in patients with stable COPD.19 In any
case, the combination of formoterol and tiotropium
allowed a sustained improvement in FEV1 up to
24 h. It must be highlighted that the effect of
treatments on SpO2, although statistically signifi-
cant, is not clinically relevant.
In this study, we examined the bronchodilation
profile of the single treatments by evaluating not
only FEV1 and FVC, but also IC because dyspnea
better correlates with changes in hyperinflation
parameters, such as IC27 and functional residual
capacity.4 Although all the explored spirometric
parameters had a similar trend over the time
(Fig. 2), the differences between the three treat-
ments were less evident when changes in IC were
considered. It is likely that, although a fast
improvement in IC can be observed after the
administration of tiotropium,28 a maintenance
treatment with this agent is required to achieve
maximal reduction in hyperinflation.16
Adverse cardiovascular effects such as heart-rate
changes, and ECG tracings may occur during
treatment with b2-agonists, and the use of a long-
acting molecule may be less favourable than the
short-acting ones.29 However, several studies on
patients with AECOPD and often older than 65 years
have been unable to demonstrate a significant
impact of a higher that customary dose of
formoterol and salmeterol both on HR and SpO2.
10
According to our previous studies, we did not find
significant changes in heart rate and SpO2, although
recently we have documented a little but signifi-
cant reduction of PaO2 after formoterol adminis-
tration,30 but it is well know that SpO2 is a less
sensitive parameter than PaO2.
In the present study, all patients suffering from
mild to moderate AECOPD were treated with
systemic corticosteroids and antibiotics, as
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suggested by international guidelines.2 Short
courses of systemic corticosteroids in AECOPD have
been shown to improve spirometric outcomes.31 In
any case, we cannot exclude that a synergistic
interaction between corticosteroids and long-act-
ing bronchodilators, with the resulting synergetic
effect being greater than the sum of responses
achieved from each drug alone, might justify the
findings of the present study. This type of syner-
getic effect has only been documented with
corticosteroids and long-acting b2-agonists.
32 and,
in effect, there is documentation that the addition
of a corticosteroid influences the fast onset of
action of formoterol.33 However, in addition to the
up-regulation of b2-adrenergic receptors and anti-
inflammatory effects by corticosteroids, part of the
beneficial effect of corticosteroids in AECOPD
therapy may include a reduction in muscarinic
receptor expression in airway smooth muscle,
allowing for easier muscle relaxation by b-adrener-
gic agonists. In fact, it has been shown that, at
least in dogs, a treatment with methylprednisolone
led to a decreased expression of both M2 and M3
muscarinic receptors in airway smooth muscle.34
More recently, it has also been documented that
dexamethasone decreases airway responsiveness to
vagal stimulation via two mechanisms: increased M2
receptor function that results in decreased acet-
ylcholine release, and increased degradation of
acetylcholine by cholinesterases.35
It must be emphasized that our study has a
number of limitations. First of all, we used a cross-
over protocol which can be controversial in patients
during AECOPD. In effect, spontaneous changes of
the bronchial obstruction level due to the systemic
therapy might have introduced a bias in the
comparison of day 1 and 5. We chose a crossover
design because it allows paired comparisons of the
results which are characterized by an higher
statistical power than unpaired comparisons. This
statistical approach is convenient for a pilot study
with a low number of enrolled patients. None-
theless, we believe that drugs randomization faced
this possible bias and, moreover, our data analysis
did not show basal differences among the three test
days and among the three drugs. In any case,
previous studies demonstrated a very slow recovery
of pulmonary function after exacerbation, with a
considerable number of patients that had not
recovered their peak-expiratory flow (PEF) to
baseline after 35 days.36 However, for a large scale
study, a parallel groups design appears to be more
appropriate. Secondly, the failure to show a
statistically significant difference between treat-
ments was likely associated with an insufficient
statistical power in the study. We believe that there
was a possibility of a type II error, which supported
the lack of significance that we have repeatedly
observed.37 This is unfortunately, one limit of the
pilot studies. Nonetheless, researchers may start
with ‘‘qualitative data collection and analysis on a
relatively unexplored topic, using the results to
design a subsequent quantitative phase of the
study’’.38 Thus, pilot studies are conducted for a
range of different reasons such as establishing
whether the sampling frame and technique are
effective, identifying logistical problems which
might occur using proposed methods, estimating
variability in outcomes to help determining sample
size, and collecting preliminary data.39 Our study
has clearly documented that the use of a combined
therapy with formoterol and tiotropium is a
possibility that is worthy of further investigation.
In conclusion, the results of this study have
documented that, although the time course of the
effects of evaluated drugs differs significantly from
that in stable COPD, with a shorter bronchodilation
both for tiotropium and formoterol, these two long-
acting bronchodilators appear to also be comple-
mentary in mild to moderate AECOPD. In fact,
whereas on the one hand formoterol ensures a fast
onset of action, which is improved by the con-
comitant inhalation of tiotropium, on the other
hand tiotropium adds prolonged and sustained
bronchodilation that is enhanced by the association
of formoterol. This finding let us to suggest a larger
evaluation of this combination in the broncholytic
treatment of AECOPD.
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